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Abstract
The threat of bioterrorism with smallpox and the broad use of vaccinia vectors for other vaccines have led to the resurgence
in the study of vaccinia immunological memory. The importance of the role of CD4+ T cells in the control of vaccinia
infection is well known. However, more CD8+ than CD4+ T cell epitopes recognized by human subjects immunized with
vaccinia virus have been reported. This could be, in part, due to the fact that most of the studies that have identified human
CD4+ specific protein-derived fragments or peptides have used IFN-c production to evaluate vaccinia specific T cell
responses. Based on these findings, we reasoned that analyzing a large panel of cytokines would permit us to generate a
more complete analysis of the CD4 T cell responses. The results presented provide clear evidence that TNF-a is an excellent
readout of vaccinia specificity and that other cytokines such as GM-CSF can be used to evaluate the reactivity of CD4+ T
cells in response to vaccinia antigens. Furthermore, using these cytokines as readout of vaccinia specificity, we present the
identification of novel peptides from immunoprevalent vaccinia proteins recognized by CD4+ T cells derived from smallpox
vaccinated human subjects. In conclusion, we describe a ‘‘T cell–driven’’ methodology that can be implemented to
determine the specificity of the T cell response upon vaccination or infection. Together, the single pathogen in vitro
stimulation, the selection of CD4+ T cells specific to the pathogen by limiting dilution, the evaluation of pathogen specificity
by detecting multiple cytokines, and the screening of the clones with synthetic combinatorial libraries, constitutes a novel
and valuable approach for the elucidation of human CD4+ T cell specificity in response to large pathogens.
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Introduction
Vaccinia virus (VACV) is the virus used in the human smallpox
vaccine. Considered the gold standard of vaccines, it was very
effective in bringing about the worldwide eradication of smallpox
disease. This vaccine, (Dryvax), is one of the two FDA approved
vaccines to smallpox in the United States (ACAM2000 was
approved in 2007). However, its use is hampered by the risk of
adverse effects and even some mortality [1]. Significant efforts
have been focusing on both the understanding of the immune
response to Dryvax/ACAM2000 and the evaluation of alternative
vaccines such as modified vaccinia Ankara (MVA).
Humans make strong CD8+ and CD4+ T cell responses after
receiving smallpox vaccination. The kinetic analysis suggests that
CD4+ responses are lower than CD8+ responses at 2 weeks post-
vaccination [2], but similar in magnitude at 1 month post-
vaccination [2–4]. Furthermore, both vaccinia specific neutraliz-
ing antibodies and CD4+ responses are detected in subjects after
more than 40 years of Dryvax immunization or variola infection
[4–7]. It is also well established that CD4+ T cells are important in
primary clearance of vaccinia and in the induction and
maintenance of long-term memory and protection from variola
challenge. In addition, CD4+ T cells assist antigen specific
antibody production, and antibodies are necessary for vaccine-
induced protection to orthopoxvirus challenge. It has been
recently demonstrated in mice that antibody specificity in response
to vaccinia virus is determined by intramolecular protein-specific
CD4+ T cell help [8]. In other words, CD4+ T cell responses to a
given protein are required for the production of antibodies to the
same protein.
The importance of the role of CD4+ T cells in the control of
vaccinia infection is well known, however more CD8+ than CD4+
T cell epitopes recognized by human subjects immunized with
vaccinia virus have been reported (search performed on January 5th,
2011 in the Immune Epitope Database website, (www.iedb.org)).
This is probably due to the fact that prediction binding algorithms
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that have been largely used to identify CD8+ specific T cell antigens
have relatively poor prognostic ability for predicting peptides that
bind class II molecules [9,10]. The vaccinia CD4+ T cell epitopes
described up to now have been derived using: 1- candidate proteins
and overlapping peptides [11,12]; 2- recombinant antigens covering
the entire predicted vaccinia virus proteome to screen CD4+ T cell
clones from vaccinated donors [13–15]; 3- MHC Class II binding
predictions for HLA-DR1 restricted peptides predicted by a
combination of P9 and Syfpeithi binding algorithms [16,17] or
EpiMatrix algorithm [18]; and 4- a two-dimensional liquid
chromatography and tandem mass spectrometry approach used
to identify vaccinia virus-derived peptides among all the peptide
antigens bound to the human class II MHC protein HLA-DR1 on
the surface of vaccinia virus infected cells [19].
Most of the studies that have identified human CD4+ specific
protein-derived fragments or peptides have used IFN-c production
by intracellular staining (ICCS) or ELISPOT to evaluate vaccinia
specific T cell responses. However, a recent study analyzing
immunological memory in a number of volunteers that have been
variola infected or vaccinia immunized demonstrated that in the
majority of the samples there was no correlation between the
proliferation to vaccinia and the presence of IFN-c-producing T
cells [5]. Interestingly, Slifka and collaborators have observed clear
intracellular TNF-a production in response to vaccinia infection
by in vitro stimulated peripheral CD4+ T cells from vaccinated
donors [4]. Based on these findings, we reasoned that analyzing a
large panel of cytokines in response to vaccinia would permit a
more complete study of T cell responses that could not have been
detected if evaluating only IFN-c production. In fact, the results
presented here confirm that TNF-a is an excellent readout of
vaccinia specificity and that other cytokines such as GM-CSF can
be used to evaluate the reactivity of CD4+ T cells in response to
vaccinia antigens. In this study we also present the elucidation of 4
novel vaccinia epitopes by directly assessing the specificity of
CD4+ T cells derived from vaccinia immunized subjects without
any assumption regarding antigen binding restriction and
independently of previous identified immunogenic candidate
proteins. This unbiased ‘‘T cell driven’’ approach used vaccinia
specific CD4+ T cell clones generated from vaccinated donors and
subsequently screened with a decapeptide positional scanning
library. The screening results in conjunction with the biometrical
analysis [20,21] performed with a vaccinia virus Western Reserve
protein database resulted in the identification of 4 novel highly
conserved vaccinia human CD4+ T cell epitopes. Furthermore, a
comprehensive analysis of the reported immunogenicity of the
vaccinia proteins from which the identified epitopes are derived
revealed that the ‘‘T cell driven’’ approach presented here results
in the identification of peptides derived from highly immunogenic
vaccinia proteins. This ‘‘T cell driven’’ approach can be readily
implemented to determine the specificity of the response following
vaccination or infection with large size pathogens for which other
methodologies could be more cumbersome.
Results
Cytokine production by vaccinia specific T cell lines and
CD4+ T cell clones in response to vaccinia infected
antigen presenting cells
A reliable and representative readout was developed to test the
vaccinia specific reactivity of T cell lines and clones derived from
PBMC of vaccinia immunized subjects [22]. Cytokine production
was chosen because it can be easily measured in a large number of
culture supernatants. The production of 22 cytokines was
simultaneously evaluated by a cytokine multiplex assay. Culture
wells included vaccinia specific CD4+ or CD8+T cell lines or CD4+
T cell clones derived from VRC19 donor in the presence of
uninfected autologous LCL or vaccinia infected autologous LCL
(LCL-Vacc). Figure 1A shows the concentration of each cytokine
produced by a VRC19 CD4+ T cell line in response to LCL-Vacc
or uninfected LCL. Additional controls included T cells, LCL-Vacc
or uninfected LCL alone. Fourteen cytokines were produced in
response to vaccinia infected LCL. Although at lower levels,
cytokines were also detected when T cells were cultured with
uninfected LCL. With the exception of IL-1a, IL-8 and MIP-1a, no
cytokines were detected in the wells with T cells, LCL-Vacc or
uninfected LCL alone. To determine the response to vaccinia by the
VRC19 CD4+ line as well as other CD4+ and CD8+ lines and two
T cell clones, the T cell response value to uninfected LCL was
subtracted from the T cell + LCL-Vacc value (Figure 1B).
Alternatively, the results were normalized by dividing the T cell+
LCL-Vacc value by the T cells + uninfected LCL background value
to give a stimulation index (SI) for each cytokine (Figure 1C). As this
study focused on CD4+ T cell specificity, only those cytokines that
were produced by CD4+ T cell lines or clones were selected. As
shown with the color formatting in Figure 1, GM-CSF, IL-2, IL-3,
IL-4, IL-13 and TNF-a were detected in high levels by most CD4+
T cell lines and clones in response to vaccinia stimulation. IFN-c
was clearly detected in the supernatants of CD8+ T cell lines and by
one CD4+T cell line (MS4) but was not detectable in other CD4+T
cell clones. Based on these results and on reagent cost consider-
ations, 6 cytokines, namely GM-CSF, IL-2, IL-4, IL-13, TNF-a and
IFN-c were selected to evaluate the vaccinia specificity of the CD4+
T cell clones. Even though the CD4+ T cell clones analyzed for the
production of 22 cytokines did not show IFN-c production, IFN-c
was included due to its known function in antiviral immunity [23]
and its frequent use in the evaluation of specific T cell responses
[24], including CD4+ responses to vaccinia [11,13,16,17].
Vaccinia lines from 3 vaccinia immunized subjects were used to
generate T cell clones, and 45 clones were established and
expanded. The clones were selected based on vaccinia reactivity
and growing characteristics. The elucidation of the specificity of 4
clones and the antigen specificity of a total of 9 clones is presented
here. Clones VRC19-16, VRC19-29, VRC19-36 were derived
from donor VRC19 and clone VRC47-38 from donor VRC47. As
shown in Figure 2, the 4 clones showed clear cytokine production
in response to autologous LCL-Vacc and PHA. However,
consistent with the results presented in Figure 1, IFN-c was not
detected in response to vaccinia infected LCL, whereas TNF-a,
IL-13 and GM-CSF were produced in a virus specific manner.
GM-CSF and TNF-a were clearly produced in response to
vaccinia. IL-4 was produced at lower levels by all 4 clones in
response to vaccinia. IL-2 was produced by all the clones in
response to vaccinia and PHA but at levels comparable to those of
background values, except for clone VRC 47-38. Based on these
results, GM-CSF and TNF-a production were selected to further
evaluate the response of the clones to vaccinia infection and for the
screening of the positional scanning library.
Elucidation of vaccinia T cell clones antigen specificity by
positional scanning peptide libraries
In order to elucidate the specificities of T cell clones VRC19-16,
VRC19-29, VRC19-36 and VRC47-38, each clone was screened
with a decapeptide positional scanning library using autologous
LCL as antigen presenting cells. At least two different screenings
were carried out for each clone. All clones showed reproducible
responses to most of the mixtures of the library as measured by
GM-CSF production. Significant and reproducible TNF-a
production was not detected in response to the peptide mixtures
Immunoprevalent Antigens in Human Smallpox Vaccine
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of the library (data not shown). Figure 3 shows the average values
obtained from 3 screenings of clone VRC19-16 with each of the
mixtures of the decapeptide library. The number of mixtures that
induce GM-CSF production (active mixtures, .50 pg/ml) varies
at each position. For example, the only active mixture in position 8
was defined with arginine (R). In positions 1, 4 and 9 more than 2
mixtures induced GM-CSF production with values .100 pg/ml.
The results obtained for each of the clones in response to the
decapeptide positional scanning library were organized in a matrix
format (as described in the Material and Methods) and are shown in
Table S1. The screening results were used to predict and rank
vaccinia stimulatory peptides by performing the biometrical
Figure 1. Cytokine production by CD4+ and CD8+ T cell lines and clones in response to antigen presenting cells infected with
vaccinia. T cells lines and clones were cultured alone or in the presence of autologous LCL (background values) or vaccinia infected LCL.
Supernatants were collected after 48 hours of stimulation and cytokine production was evaluated by multiplex assay as described in Materials and
Methods. A. Cytokine production by VRC 19 CD4+ lines and control cultures is expressed in pg/ml. B. Normalized values resulting from the subtraction
of background values from pg/ml produced by various lines and clones in response to vaccinia infected LCL are shown. C. Each value represents the
stimulation index (SI) resulting from dividing the pg/ml produced in response to vaccinia infected LCL by the background values.
doi:10.1371/journal.pone.0024091.g001
Immunoprevalent Antigens in Human Smallpox Vaccine
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analysis [20,21] as described in the Materials and Methods section.
The biometrical analysis was performed using a custom Western
Reserve Vaccinia protein database which consisted of 216 proteins
and a total of 55,892 decapeptides which were scored using the
matrix for each of the clones. For each individual clone the highest
scoring vaccinia peptides (15–35 peptides of a total of 55,892
scored peptides) were synthesized and tested for their stimulatory
potencies at 10 mg/ml and 1 mg/ml with their respective T cell
clone in the presence of autologous LCL. Positive control wells
with T cells + LCL-Vacc and negative controls with T cells +
uninfected LCL were also included in each experiment. Table S2
summarizes the GM-CSF and TNF-a secretion levels for each of
the clones in response to the peptides synthesized and tested for
each clone. All clones responded to the first or second ranked
Figure 2. Cytokine production by vaccinia specific CD4+ T cell clones in response to vaccinia infected autologous LCL. Clonal T cells
(2.56104) were cultured alone, stimulated with PHA or in the presence of 56104 autologous LCL or vaccinia infected LCL (LCL-Vacc). Supernatants
were collected after 48 hours and cytokine production was evaluated by multiplex assay. Data represents the average of the cytokine concentrations
determined in the supernatant of two replicate culture wells.
doi:10.1371/journal.pone.0024091.g002
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predicted peptide. The identified peptides for each of the clones
and the information for the proteins from which these peptides are
derived are summarized in Table 1.
The stimulatory activity of the identified peptide for each clone
was tested in a dose response manner with its respective clone.
Figure 4 shows that the GM-CSF and TNF-a production are dose
dependent for all the clones in response to peptide, and the
peptides are highly stimulatory at low concentrations. Interesting-
ly, for all the clones, GM-CSF production is detected at lower
peptide concentrations than TNF-a production, which correlates
with the observation that GM-CSF and not TNF-a was detected
in response to peptide mixtures of the positional scanning library.
In summary, 4 novel vaccinia CD4+ T cell epitopes have been
identified using GM-CSF production by CD4+ T cells as the
readout of activity to peptide mixtures of a decapeptide positional
scanning library.
Multi-cytokine production analysis in response to
vaccinia CD4+ epitopes
The multi-cytokine production was evaluated by a multiplex
assay in the supernatants of 6-hour and 48-hour cultures
stimulated with peptide at 4 different concentrations (3,000, 400,
40 and 5 ng/ml). Figure 5 shows the cytokine production at
6 hours and 48 hours with 400 ng/ml and 5 ng/ml of peptide.
LCL-Vacc or PHA was used as stimuli and control background
wells with T cells + uninfected LCL were included. In addition to
GM-CSF and TNF-a, most of the clones secreted large amounts of
IL-13, IFN-c, IL-4 and IL-2 in response to 400 ng/ml of peptide
and this production could be detected at 6 hours and 48 hours
post-stimulation. Interestingly, when low concentrations of peptide
were used for stimulation (5 ng/ml), clear differences were
observed at the 2 different time-points evaluated. IL-4, IFN-c
and TNF-a were undetectable or produced at very low levels by
only 1 of the 4 clones at 6 hours. In addition, at 6 hours post-
stimulation IL-2 was detected in the culture supernatants of 3 of
the 4 clones and GM-CSF and IL-13 in 2 of the 4 clones.
However, in 48 hours supernatants, IL-2 was undetected in 3 of
the 4 clones whereas GM-CSF and IL-13 were not only detected
in 3 of the 4 clones but were also produced in large quantities
(.1000 pg/ml). IFN-c was only detected upon peptide stimulation
(400 ng/ml) but not with LCL-Vacc. In addition, IFN-c
production was detected in response to 5 ng/ml of peptide only
for clone VRC19-29. PHA stimulation triggered the secretion of
all six cytokines analyzed. The level of production of TNF-a, IFN-
c, IL-4 and IL-2 in response to PHA was similar between 6 and
48 hours probably indicating that there is a maximal cytokine
response of the clones to PHA and that response is achieved at
6 hours post-stimulation. This finding is in agreement with kinetics
of cytokine gene expression reported by Abdalla et al [25]. In
contrast, the level of GM-CSF and IL-13 did increase from
6 hours to 48 hours, showing again that in particular these two
cytokines accumulate at high levels in the supernatants of
stimulated CD4+ T cell clones. In response to infection (LCL-
Vacc), all cytokines, with exception of IFN-c, were detected in all
clones and, similarly to the response to low antigen concentration
(peptide at 5 ng/ml), GM-CSF, TNF-a, IL-13 and IL4 were
detected at 48 hours at significantly higher levels than those at
6 hours. The multiplex analysis also revealed that clones VRC19-
29 and VRC47-38 are more reactive to their specific peptides than
the other 2 clones producing higher levels of cytokines at lower
peptide concentrations.
Intracellular cytokine production of vaccinia specific
CD4+ T cell clones in response to peptide and vaccinia
stimulation
Intracellular cytokine staining (ICCS) studies were carried out to
measure the production of GM-CSF, IFN-c IL-13, and TNF-a by
each CD4+ T cell clone in response to vaccinia infected LCL and
to the vaccinia peptides at a single cell level (Figure 6). CD4+ T
cell clones were cultured in the presence of LCL-Vacc, peptide-
loaded LCL or uninfected LCL for 6 hours. The percentage of
cells producing each of the cytokine, irrespective of whether they
produce only one or multiple cytokines, is shown in Figure 6A. All
clones produced GM-CSF, IFN-c, IL-13 and TNF-a in response
to their specific vaccinia peptide. Clearly, the percentage of
cytokine-producing cells is higher in clones VRC19-29 and
VRC19-36. Furthermore, TNF-a producing cells in response to
LCL-Vacc were detected in all clones, whereas the percentage of
cells producing GM-CSF, IFN-c and IL-13 was either low or not
detected. The contribution of the 15 different possible cytokine
combinations based on GM-CSF, IFN-c, IL-13 and TNF-a
production to the total cytokine production was assessed for each
clone (Figure 6B). This analysis determines the cytokines that were
produced by the largest percentage of cells within the overall
percentage of cytokine producing cells. For clones VRC19-16 and
VRC47-38, the largest percentage of cytokine producing CD4+ T
cells in response to peptide (55% and 40% respectively) is
represented by cells that only produce TNF-a and no other
cytokine (Figure 6B). In contrast, for clones VRC19-29 and
VRC19-36 the dominant subset (55% and 38%, respectively) in
response to peptide is represented by cells that produce all four
cytokines simultaneously. Remarkably, in response to vaccinia
stimulation, the largest percentage of cytokine producing CD4+ T
cells for all 4 clones is represented by cells that only produce TNF-
a and no other cytokine. Overall, these results show that within
6 hours of stimulation, the identified vaccinia peptides induce T
cell clones that produce multiple cytokines while in response to
vaccinia infected LCL the largest percentage of cells produce only
TNF-a.
CD4+ vaccinia T cell clones are cytotoxic
It has been previously demonstrated that vaccinia specific
CD4+ T cell clones can recognize and kill vaccinia infected
targets [26], but there have been few studies focusing on cytotoxic
CD4+ T cell responses to smallpox vaccination [17]. The four
CD4+ T cell clones identified in this study were tested for their
cytotoxic activity against LCL-Vacc and their specific vaccinia
peptides. As shown in Figure 7, all CD4+ T cell clones killed
vaccinia infected cells. VRC19-16, VRC19-36 and VRC47-38
killed vaccinia peptide loaded LCL in a dose dependent manner
and at comparable or higher efficiency than vaccinia infected
target cells. VRC19-29 killed peptide loaded LCL at a very low
percentage and the killing was not proportional to the amount of
peptide tested. The reason for the lack of cytotoxic activity in
response to peptide by VRC19-29 is unknown and suggests that
some other factors might be present in the vaccinia infected cells
and not in the peptide target cells that render the cells susceptible
to killing. In general, these results demonstrate that these CD4+
T cell clones are cytotoxic in agreement with the view that CTL-
mediated lysis of vaccinia virus may significantly contribute to the
effect of the vaccine in controlling the virus infection with
poxvirus [17,27].
Immunoprevalent Antigens in Human Smallpox Vaccine
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Characterization of the HLA restriction haplotype for the
identified peptides
To determine the HLA restriction context in which the peptides
are presented, T cell clones together with uninfected LCL were
cultured with peptide in the presence of antibodies that recognize
the major HLA loci, namely anti–HLA-DR, anti–HLA-DQ, anti–
HLA-DR/DQ/DP or human IgG2a as an isotype control. T cell
clones were also tested with LCL-Vacc in the presence or absence
of the same antibodies. At least 50% inhibition of GM-CSF and
TNF-a production and a consistent pattern in duplicate tests of
each mAb was required to assign restriction to any HLA locus.
Cytokine production was inhibited for all the clones in response to
peptide or vaccinia infection in the presence of antibody anti-
HLA-DR (Figure 8). For clones VRC19-29 and VRC47-38 the
quantification of GM-CSF production did not reveal any
inhibitory effect by any of the antibodies (data not shown).
However, inhibition could be observed when TNF-a production
was quantified. On the contrary, the inhibitory effect of the
antibodies on the peptide stimulated T cell clones VRC19-16 and
VRC19-36 was determined from the production of GM-CSF.
These results clearly suggest that the 4 peptides are presented to
their specific clones in the context of HLA-DR restriction.
To further characterize the DR restriction, B cell transfectants
(BLS) cells expressing only 1 single haplotype were used as antigen
presenting cells. The available BLS express either the DRB1*1501
or DRB5*0101 haplotype. Since VRC19 donor expresses the
DRB1*1501 DRB5*0101, DRB1*0701 and DRB4*0103 alleles,
BLS cells expressing DRB1*1501 or DRB5*0101 were used to
present the D13L-YID, E1L-MYT and A6L-SFW peptides. As
shown in Figure S1, D13L-YID and E1L-MYT peptides are
presented in the context of DRB1*1501 to VRC19-16 and
VRC19-29 clones, respectively. However, none of these alleles
were able to present the A6L-SFW peptide to clone VRC 19-36
indicating that another haplotype than DRB1*1501 DRB5*0101
is used to present the A6L-SFW peptide in donor VRC19.
Recognition of peptides by vaccinia specific T cell lines
To evaluate the recognition of the identified vaccinia CD4+
peptides in bulk populations, short term vaccinia specific T cell
lines were derived directly from PBMC from donors VRC19 and
VRC47. As noted in the methods, donor VRC47 had been
vaccinated with Dryvax once, and donor VRC19 had been first
vaccinated with MVA and then boosted with Dryvax. The two
time-points samples from donor VRC19, post-MVA (19-MVA)
and post Dryvax (19 Dvax), were included. Donor TPI10, who
was never vaccinated against smallpox, was included as control.
The reactivity to the peptides was analyzed by intracellular
staining of IFN-c and TNF-a production in both CD4+ and
CD8+ subsets. Vaccinia stimulation and PHA were used as
positive controls. As shown in Figure 9A, analysis in VRC19
donor, after MVA vaccination (19-MVA), showed IFN-c and
TNF-a production by CD8+ T cells but not CD4+ specific
responses following vaccinia stimulation (CD4-Vacc and CD8-
Vacc subsets). However, both CD4+ and CD8+ subsets clearly
responded to PHA stimulation (CD4-PHA and CD8-PHA subsets)
demonstrating that the lack of vaccinia CD4+ specific responses
was not due to an experimental error or to the absence of a
generalized lack of reactivity of the CD4+ population. T cells from
this donor upon boosting with Dryvax (19-Dryvax) showed both
CD4+ and CD8+ specific T cell responses to vaccinia, suggesting
that boosting with Dryvax vaccination clearly expands the CD4+
specific vaccinia responses. Importantly, whereas the CD8+
response to vaccinia in this sample was characterized by cells that
produce both TNF-a and IFN-c cytokines, the CD4+ response
was represented by cells that only produce TNF-a or by cells that
produce TNF-a and IFN-c. Similarly, vaccinia specific CD4+ T
cells from donor VRC47 upon Dryvax immunization (47-Dryvax)
produced either TNF-a, or TNF-a and IFN-c, but not IFN-c
alone, whereas the CD8+ population produced mostly TNF-a and
IFN-c. As expected, T cells derived from the nonimmunized
donor TPI10 responded clearly to PHA stimulation but not to
vaccinia infection.
Figure 9B shows the intracellular cytokine response to the
peptides. Although vaccinia CD4+ responses were not observed in
sample 19-MVA when vaccinia infected LCL were used for
stimulation (Figure 9A), clear CD4+ T cell responses to vaccinia
epitopes A6L-SFW and F3L-DWV were detected (Figure 9B, top).
This response was characterized by TNF-a (+) and IFN-c (2)
Table 1. Characteristics of identified vaccinia CD4+ epitopes.
Clonea Epitope VACV-WR Protein Residues
%
Homologyb Descriptionc Abbreviation
VRC19-16 (Vb8) YIDAYVSRLL VACV-WR118 D13L 283-292 100 rifampicin target associates with inner surface
immature virus membrane
D13L-YID
VRC19-29 (Vb4) MYTYFSNTIL VACV-WR057 E1L 396-405 100 poly-A polymerase catalytic subunit VP55 E1L-MYT
VRC19-36 (Vb8) SFWFLKSGAV VACV-WR125 A6L 75-84 100 unknown A6L-SFW
VRC47-38 (Vb2) DWVSSHSKSL VACV-WR052 F13L 361-370 100 palmytilated EEV membrane protein;
phospholipase motif, required for IEV formation
F13L-DWV
aVb determination by FACS with exception of VRC19-16 determined by PCR.
bwithin vaccinia and variola strains.
cfrom Ortholog list in poxvirus.org.
doi:10.1371/journal.pone.0024091.t001
Figure 3. Screening profile of clone VRC19-16 in response to the decapeptide positional scanning library. The GM-CSF production (pg/
ml) elicited by VRC19-16 T cells in response to each mixture of the decapeptide library was measured. 2.56104 VRC19-16 T cells were cultured in the
presence of 56104 autologous LCL and each library mixture at a final concentration of 200 mg/ml. After 48 hours the GM-CSF production was
evaluated in the culture supernatants by ELISA. Values represent average of 3 different screenings with duplicate culture wells for a total of 6
replicates. The x axis in each plot indicates the defined amino acid (one letter code) in each of the mixtures of the library. In each position, the amino
acid corresponding to the amino acid present in the identified vaccinia peptide D13L-YID is indicated (*).
doi:10.1371/journal.pone.0024091.g003
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producing cells. CD8+ T cells from 19-MVA not only responded
to these epitopes but also recognized D13L-YID and E1L-MYT
(Figure 9B, bottom). While the CD8+ T cell response to A6L-SFW
and F3L-DWV was characterized by cells that produce TNF-a
and not IFN-c, the CD8+ response to D13L-YID and E1L-MYT
was represented by cells that produced either TNF-a or IFN-c
alone. Both CD4+ and CD8+ T cells derived from 19-Dryvax and
47-Dryvax samples responded to all 4 vaccinia epitopes, but CD8+
T cells showed a lower percentage of cytokine producing cells. In
both donors, after Dryvax vaccination, the CD4+ response to the
peptides was characterized by cells that produced either TNF-a or
TNF-a and IFN-c, but not IFN-c alone. T cells from unvaccinated
TPI10 control subject did not respond to any of the vaccinia
epitopes identified in this study. Together, the results shown here
demonstrate that vaccinia specific responses can be detected in
vaccinated donors using the vaccinia epitopes identified in this
study and highlight the importance of evaluating TNF-a as well as
IFN-c production in order to determine the CD4+ specificity of
the smallpox vaccination response in humans.
Discussion
During the past 10 years significant efforts have been focused on
the understanding of the immunity and immunological memory to
vaccinia virus and other poxviruses (reviewed in ref. [28].
Particularly, it has been shown that both, CD8+ and CD4+ T
Figure 4. GM-CSF and TNF-a production by vaccinia specific CD4+ T cell clones in response to the identified vaccinia peptides. Each
vaccinia CD4+ T cell clone (2.56104) was stimulated for 48 hours in the presence of autologous LCL (56104) and peptide in a dose response assay at
the indicated concentrations. GM-CSF and TNF-a was measured in the culture supernatants by ELISA. Values represent the average cytokine
production in two independent duplicate wells and are derived from one representative experiment out of three.
doi:10.1371/journal.pone.0024091.g004
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Figure 5. Cytokine production by CD4+ T cell clones. Vaccinia peptides were tested in a dose response assay with their specific T cell clone
(2.56104) in the presence of autologous LCL (56104) in duplicate wells. Graphs show the cytokine production in response to 5 and 400 ng/ml of
peptide (values for background wells were subtracted) at 6 hours and 48 hours post-stimulation. T cell clones were cultured in the presence of
autologous LCL (background), vaccinia infected LCL (LCL-Vacc) or PHA. Cytokine production was evaluated by multiplex assay.
doi:10.1371/journal.pone.0024091.g005
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cells respond vigorously following smallpox vaccination of humans
[4]. The kinetic analysis of CD4+ versus CD8+ responses suggests
that the CD4+ response is lower than the CD8+ at 2 weeks post-
vaccination [2], but similar in magnitude at 1 month post-
vaccination [2–4]. Furthermore, both vaccinia specific neutraliz-
ing antibodies and CD4+ responses are detected in subjects after
more than 40 years of Dryvax immunization [4–6] or variola
infection [5,7]. In a murine model of vaccinia infection it has been
recently demonstrated that there is a strong concordance between
CD4+ T cells and antibody protein targets. In fact, this study
demonstrated that 11 out of the 18 proteins recognized by CD4+
T cell responses were also detected by antibodies [8]. It is also well
established that CD4+ T cells are important in primary clearance
of vaccinia and in the induction and maintenance of long-term
memory and protection from variola challenge. Importantly,
Puissant-Lubrano in a recent study showed that the number of
Figure 6. Intracellular cytokine production by vaccinia specific CD4+ T cell clones. Each clonal T cell population was stimulated with
10 mg/ml of its specific vaccinia peptide in the presence of autologous LCL or vaccinia infected LCL for 6 hours. Brefeldin A was added to the cultures
after 1 hour of initial incubation and the intracellular cytokine production was measured as described in the Material and Methods section. The
percentage of CD4+ T cells producing each individual cytokine (A) or any of the 15 possible combinations of cytokines (B) is shown. The largest
subset of CD4+ T cells (out of the 15 possible combinations of cytokines) for each clone in response to peptide or vaccinia infected LCL is shown as
percentages above the corresponding data bars (B). Results are representative of two experiments.
doi:10.1371/journal.pone.0024091.g006
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residual vaccinia-specific CD4+ lymphocytes (but not CD8+) is
inversely associated with the size of the skin lesion formed in
response to revaccination in humans [29]. Together, these findings
clearly support the importance of CD4+ T cells in long term
memory to vaccinia infection.
The elucidation of antigen specificity in response to vaccinia
immunization has been more difficult for CD4+ than for CD8+ T
cells. This could be explained in part by the fact that most CD8+
T cell epitopes have been identified using prediction binding
algorithms which have relatively poor prognostic ability for
prediction of peptides that bind class II molecules [9,10]. In
addition, the use of traditional readouts of CD8+ specificity, such
as IFN-c detection to characterize CD4+ T cell responses, could
have underestimated the frequency of CD4+ responses and
therefore precluded the understanding of CD4+ specificity. With
this in mind, we hypothesized that a comprehensive characteriza-
tion of the CD4+ T cell response to vaccinia could reveal better
readouts of specificity to enumerate and characterize responses
that otherwise would have not been detected. In this study, we
implemented an approach in which PBMC from human
immunized donors were a single time in vitro stimulated with
Figure 7. Cytotoxic activity of vaccinia CD4+ T cell clones. Clonal
T cells were co-cultured with 51Cr-labeled autologous LCL targets
(26103), infected with vaccinia or seeded in the presence of vaccinia
peptides at 5, 1 and 0.2 mg/ml. The cytotoxicity activity is expressed as
the mean of the percent of specific lysis triggered by the cytotoxic T cell
clones after 4 hours at a 30:1 ratio. These results are representative of
three experiments.
doi:10.1371/journal.pone.0024091.g007
Figure 8. Determination of HLA restriction. Cytokine production for each T cell clone was evaluated following the activation with their specific
vaccinia peptides in the presence and absence of HLA blocking antibodies and isotype control anti-human IgG2a. T cells (2.56104) were seeded with
autologous LCL (56104) and peptide and supernatants were collected after 48 hours of incubation. Data represents averages and standard errors of
the mean of TNF-a or GM-CSF concentrations in the supernatant of two replicate culture wells in the presence of 10 mg/ml of antibody and 0.4 ng/ml
of peptide, with the exception of peptide A6L-SFW that is shown at 370 ng/ml. Results are representative of two individual experiments.
doi:10.1371/journal.pone.0024091.g008
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vaccinia virus, and the resulting CD4+ T cell lines and clones were
characterized in terms of their cytokine production (22 cytokines,
Figure 1). Positive responses were observed for 14 of the 22
cytokines tested, namely GM-CSF, IFN-c, Il-2, IL-3, IL-4, IL-5,
IL-6, IL-8, IL-10, IL-12(p40), IL-13, IP-10, Rantes and TNF-a.
Six of these cytokines (GM-CSF, IFN-c, IL-2, IL-4, IL-13, TNF-a)
were selected to characterize both the vaccinia and the peptide
responses by CD4+ T cells and all were found to be positive. Our
results show that the agonistic activity of the peptides and the
response to vaccinia infection is enough to induce a large spectrum
of cytokines. Indeed, ICCS revealed that both Th-1 and Th-2
cytokines are being produced simultaneously by the same clonal
cells in response to peptide, demonstrating that the clones cannot
necessarily be assigned to any particular CD4+ Th-subset.
Furthermore, all 4 vaccinia CD4+ T cell clones showed the
capacity to kill vaccinia infected targets and vaccinia peptide
loaded APCs. However, the concentration of antigen required to
trigger cytotoxic T cell responses are higher than those needed to
induce cytokine production. Together, our studies show that the
vaccinia clones studied here are poly-functional and suggest that
the detection levels of each of those functions depend on the
amount of antigen used for stimulation.
The detection of GM-CSF in response to mixtures of a
positional scanning library was found to be an optimal and reliable
readout of CD4+ activation and led to the identification of 4 novel
immunogenic vaccinia epitopes derived from proteins prevalently
recognized by CD4+ T cells and antibodies upon smallpox
vaccination in humans. Previously, GM-CSF was measured in the
serum of vaccines in an effort to correlate adverse effects with the
presence of cytokines [30,31] but, to our knowledge, this is the first
time that GM-CSF is monitored and is shown to be clearly
produced by T cells in response to vaccinia.
Figure 9. Intracellular cytokine production by vaccinia specific T cell lines. Vaccinia T cells lines were generated with PBMCs from
vaccinated donors VRC19 and VRC47, and from unvaccinated donor TPI10 as detailed in the Material and Methods section. T cell lines were evaluated
for their recognition of vaccinia virus and the vaccinia peptides by intracellular TNF-a and IFN-c production. Data represent the percentage of CD4+
or CD8+ T cells in each line producing either of the four possible combination of cytokines in response to vaccinia infected autologous LCL and PHA
(A) or to the identified vaccinia peptides (10 mg/ml) (B).
doi:10.1371/journal.pone.0024091.g009
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The determination of cytokine production at decreasing
concentrations of peptide clearly showed that the production of
GM-CSF requires less peptide than TNF-a (Figure 4). This finding
explains why GM-CSF and not TNF-a was detected in response to
mixtures of the positional scanning library composed of billions of
different peptides present at very low concentrations. To our
knowledge, this study shows for the first time that lower antigen
concentrations are required for substantial production of GM-CSF
as compared to other cytokines. Its detection after 6 hours and its
increase after 48 hours (Figure 5) are in agreement with a report
by Abdalla et al in which mRNA of GM-CSF is detectable as fast
as 30 minutes after stimulation of CD4+ T cells with a recall
antigen (purified protein derivative) and it is maintained at high
levels over a period of 96 hours [25]. Furthermore, no other
evaluated cytokine (IL-2, IL-5, IFN-c, TNF-a) maintained the fold
increase observed for GM-CSF. Topalian et al, also suggested the
lower antigen concentration requirement for GM-CSF production
[32]. In this study, CD4+ T cells produced GM-CSF at
significantly higher levels than TNF-a, IL-4, and IFN-c in
response to tumor lysates. While GM-CSF is not a standard
cytokine used for monitoring human T cell responses against
vaccines or infection, its production by activated T cells is
generally accepted. A review by Shi et al in 2006 describes its
immunobiology specifically in T cells [33], and more recently a
number of studies have demonstrated the advantages of
monitoring T cells expressing GM-CSF in the context of infection
[34,35], and vaccine responses to bacterial [36] and tumor
antigens [37].
Similar results were obtained either by ICCS (Figure 6) or by
measuring the cytokines in the culture supernatants (Figure 5)
when the T cell clones were stimulated with their specific vaccinia
peptides for 6 hours. In contrast, in response to vaccinia infection
(LCLs-Vacc) ICCS revealed that the large majority of the cytokine
producing cells produce only TNF-a (52% to 95% depending on
the clone) whereas measurement of the same cytokines in the
culture supernatants show that GM-CSF, IL-13 and TNF-a are
clearly detected. It is therefore important to note that different
readouts of activation, antigens, and times of stimulation provide
multiple snapshots of the same dynamic process. Indeed, the
importance of monitoring multiple cytokines when analyzing the
T cell response to vaccination and infection has been previously
reported. However, in response to vaccinia very few studies have
looked at cytokines other than IFN-c production. Hammarlund et
al [4] monitored TNF-a and IFN-c producing vaccinia specific T
cells by ICCS, and Ryan et al [38] studied the production of 11
cytokines in response to vaccinia, but they did not include TNF-a,
GM-CSF and IL-13 which we identified in the present study to be
clearly produced by vaccinia specific T cell clones. In addition, it is
clear that a significant percentage of peptide and vaccinia specific
T cells in bulk populations can only be detected by ICCS by the
measurement of TNF-a production (Figure 9A and 9B). Together,
these results may explain the intriguing observation [17] that in
bulk PBMC cultures, the total numbers of IFN-c secreting cells
responding to the individual peptides is higher than the number of
IFN-c secreting cells responding to whole vaccinia virus. Our
findings support the idea that quantifying only IFN-c producing
cells underestimates the CD4+ T cell response to vaccinia virus.
Furthermore, Jing et al showed that CD4+ responses to a group of
vaccinia fragments were considered positive by proliferation but
negative by IFN-c quantification [14]. In addition, results with
dengue virus also showed that the majority of CD4+ cytokine-
positive T cells from donors immunized with the live attenuated
vaccine produced either TNF-a alone or TNF-a and IFN-c when
stimulated with heterologous antigen serotypes [39].
The results presented here show that human vaccinia specific
CD4+ T cell clones that emerge following smallpox vaccination
produce high levels of IL-13 in response to vaccinia and peptide
stimulation. Furthermore, vaccinia specific T cell lines and ex-vivo
responses in PBMC from vaccinated donors also respond with IL-
13 secretion upon in vitro vaccinia stimulation (Figure 1 and data
not shown). The role of IL-13 on vaccinia infection has been
studied in the context of atopic dermatitis and its effect on vaccinia
growth in keratinocytes has been reported [40,41]. In addition, it
has been shown that following smallpox immunization [2] a small
proportion of vaccinia specific CD4+ T cells produce exclusively
IL-13 during the peak effector phase of the response (2 weeks
following Dryvax vaccination). Huaman et al showed that in
humans, immunization with a fragment of Plasmodium falciparum
triggers memory CD4+ T cells that produce IL-13 [42]. In this
regard, it has been suggested that the production of an appropriate
amount of IL-13 during infection could moderate the degree of
pathogen-induced inflammation. Particularly, data generated in a
rat model of parainfluenza type 1 (Sendai) virus infection indicated
that appropriate secretion of IL-13 could also serve to limit the
extent of virus-induced inflammation [43]. Whether IL-13 has a
role in long term protection upon vaccination cannot be
concluded from these results, but it is clear that quantification of
IL-13 secretion by CD4+ T cells could be used to follow up and
characterize vaccinia responses upon vaccination.
It is interesting that although all the clones produced IFN-c in
response to PHA and peptide, it was not detected in response to
vaccinia infected LCLs when measured in the culture supernatants
upon 48 hours of stimulation. In addition, all the clones showed
IFN-c production when measured by ICCS upon peptide
stimulation and at a lower level upon vaccinia stimulation
(Figure 6, VRC19-16 and VRC19-29 clones). The most likely
explanation for the lack of correlation on the intracellular
detection of IFN-c, but not in the supernatant cultures upon
vaccinia stimulation, is the expression of IFN-c binding proteins
(IFN-c BPs) by vaccinia virus. IFN-c BPs have been reported to
efficiently bind and antagonize soluble IFN-c [44,45]. An
alternative explanation derives from studies reported by Zaunders
et al in which they show that IFN-c production is characteristic of
effector CD4+ T cells at very early time-points upon vaccination,
but IFN-c levels decrease as much as 10-fold lower than other
indicators of vaccinia specificity during memory T cell differen-
tiation [46].
In this study vaccinia specific CD4+ T cell clones from human
immunized subjects were screened with combinatorial peptide
libraries. The screening data was then integrated by a computa-
tional analysis, known as positional scanning based biometrical
analysis [20], with a vaccinia specific protein database for the
prediction of stimulatory peptides. Positional scanning libraries
have been extensively and successfully used for the identification of
T cell epitopes in a broad range of human diseases [47–50]. The
positional scanning library profile for each of the vaccinia clones
revealed that the amino acids of the identified peptides in most of
the positions correspond to the defined amino acids of the
mixtures with the highest stimulatory potency (shown in Table S1).
The high correspondence on amino acids from active mixtures in
the active peptides identified for the vaccinia clones is similar to
previous results obtained with other pathogen specific T cell clones
[51] and confirms that the use of positional scanning libraries
together with the biometrical analysis provides an efficient
unbiased methodology for epitope and antigen identification.
Our previous studies on T cell pathogen specificity have shown
that more than one peptide can be recognized by a single
pathogen specific T cell clone [47,49,52]. However, this was not
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the case in this work in which only one vaccinia epitope was found
to stimulate each of the clones. A possible explanation for this
finding is that we have used a vaccinia virus (Western Reserve)
protein database instead of the complete viral database (Vaccinia:
216 proteins and 59,892 decapeptides versus Viral Genpept 156:
506,176 proteins and 125,055,759 decapeptides). Alternatively,
the vaccinia clones presented here are intrinsically not highly
cross-reactive and thus, independent of the database used for the
biometrical analysis, there is only one (the peptides identified in
this study) or very few optimal peptides capable of triggering their
activation. Indeed, the biometrical analysis of the viral database
revealed, for 3 of the 4 clones, that the identified vaccinia peptide
in this work ranked within the top 30 peptides for the 125 million
peptides scored (data not shown). Although all these peptides were
not synthesized and tested, and thus their possible agonistic
activity has not been determined, this finding strongly suggests that
the clones are highly specific for the antigens reported here.
Importantly, the epitopes identified by positional scanning
peptide libraries and their corresponding proteins are by definition
immunogenic, since they have been derived by interrogating
vaccinia specific T cell clones expanded in vivo during exposure to
the vaccine, and hence relevant to the immune response. Other
groups have also reported the clear advantages of using ‘‘T cell
driven’’ approaches for the identification of antigens recognized by
large size pathogens specific T cells. The T cell driven approach
resulted in the identification of immunodominant epitopes for
Mycobacterium tuberculosis with a genome encoding for approximate-
ly 4,000 proteins [53]. The methodology implemented in our
study used a single in vitro vaccinia virus stimulation of PBMC
derived from smallpox immunized subjects in order to expand and
clone vaccinia specific T cells. While it is possible that this
stimulation may result in the expansion of cross-reactive T cells
that were not originally triggered by the in vivo vaccinia
immunization, our data shows that vaccinia specific T cells are
only expanded in vaccinia immunized donors and not in
unvaccinated subjects (Figure 9 and data not shown) indicating
that the one time in vitro expansion with the virus expands the
repertoire triggered by immunization.
Four novel vaccinia epitopes and their corresponding vaccinia
antigens (Table 1) recognized by CD4+ T cells from humans
immunized with the smallpox vaccine are presented in this study.
D13L-YID and F13L-DWV proteins are from late expression
membrane proteins, E1L-MYT from an early expression enzyme,
and A6L-SFW is from a protein with unknown function and late
expression. All four proteins have 100% homology within vaccinia
and variola strains. In addition, and in agreement with recent
findings by Jing et al showing that HLA-DR dominates the
presentation of vaccinia antigens to CD4+ T cells [15], all four
identified epitopes in this study were found to be HLA-DR
restricted. The identification of the epitopes presented here used a
T cell driven approach that has not been previously utilized to
identify immunogenic pathogen proteins following vaccination in
humans. This approach elucidates the peptides and viral antigens
recognized by virus specific T cells using an unbiased collection of
peptides (positional scanning libraries) presented by autologous
LCLs. Thus, no previous knowledge about MHC restriction or
antigen specificity is required.
To evaluate the performance efficacy of the T cell driven
strategy presented here we compared the extent of recognition by
antibodies and CD4+ T cells of each of the 181 vaccinia proteins
derived from all reported human studies. Using separately the
information from CD4+ T cell [13] or antibody responses [13,54–
57], we calculated a percentage of recognition for each vaccinia
protein by dividing the number of subjects that showed protein
recognition by the total number of subjects tested (76 or 126 for
antibodies and 11 for T cells). Based on the overall distribution of
the percentages of recognition and the number of subjects tested
we established a cutoff of .40% and .10% for CD4+ T cell or
antibody responses, respectively for a protein to be considered
predominantly recognized. Using these thresholds 31 proteins
were determined as predominantly recognized by CD4+ T cells
and 21 by antibodies (data not shown, manuscript in preparation).
Table 2 shows the function, temporal expression [58] as well as the
percentage of recognition for each of the 10 proteins (4 reported
here and manuscript in preparation) that we have identified using
T cell driven approaches. Strikingly, 6 out of the 10 identified
proteins (D13L, A7L, F13L, A6L, A10L and H5R) are within the
31 predominantly recognized proteins by CD4+ T cells (percent-
age of recognition .40%) and 5 (D13L, F13L, H5R, A10L and
L1R) are within the 21 predominantly recognized proteins by
antibodies (percentage of recognition .10%). The significance of
our results can be statistically analyzed by comparing the
probability of these findings to random sampling. If a random
sample of 10 proteins were selected from the 180 proteins analyzed
by CD4+ T cell responses, the probability that 6 or more would be
among the 31 predominantly recognized proteins would be only
0.21%. Similarly, if a random sample of 10 proteins were selected
from the 181 proteins analyzed by antibody responses, the
probability that 5 or more would be among the 21 predominantly
recognized proteins would be 0.23%. The percentage of
predominantly recognized proteins that we identified is about
60%, which is clearly larger than the random probabilities, and
indeed the above probabilities indicate that the method used in the
present study yields results significantly better than random
selection. These findings clearly reveal that the T cell driven
approach used in the present study is very efficient in the
identification of immunogenic and predominantly recognized
proteins. Since the analysis of the whole pathogen proteome to
identify relevant antigens might not be feasible for larger
pathogens (.1,000 proteins), there is a clear advantage in using
positional scanning libraries to elucidate the antigen specificity of
the pathogen specific T cells.
In conclusion, we describe a methodology that can be
implemented and applied to determine the specificity of the T
cell response upon vaccination or infection with large size
pathogens for which other methodologies would be more limiting.
Together, the single pathogen in vitro stimulation, the selection of
CD4+ T cells specific to the pathogen by limiting dilution, the
evaluation of pathogen specificity by detecting multiple cytokines
(including GM-CSF), and the screening of the clones with
synthetic combinatorial libraries constitutes a novel and valuable
approach for the elucidation of the CD4+ T cell specificity in
response to large pathogens in human samples. We believe that
further efforts on the development of miniature T cell activation
assays will be extremely beneficial to reduce the number of clonal
CD4+ T cells required to test combinatorial peptide libraries and
to be able to define the spectrum of specificities with higher
throughput.
Finally, our results support the notion that the cytokines selected
to profile CD4+ T cell specific responses upon infection or
vaccination should not rely only in IFN-c secreting cells, but on
the assessing of multi-cytokines at different time-points and by
using different readout technologies. We believe that the vaccinia
antigens identified in this study contribute to the knowledge base
of the human immune response to vaccinia immunization and
could lead to the development and evaluation of novel and safer
smallpox vaccines.
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Materials and Methods
Donors
Peripheral blood mononuclear cells (PBMC) from modified
vaccinia Ankara (MVA) and/or Dryvax-immunized donors were
made available from a clinical study carried out at the Vaccine
Research Center, NIH [22]. These studies were approved by and
performed in compliance with the guidelines of the National
Institute of Allergy and Infectious Diseases Institutional Review
Board, and were performed in accordance with 45 CFR Part 46,
U.S. Food and Drug Administration regulations. All subjects
signed written informed consent documents. Subject VRC19
received a single injection of MVA and a subsequent challenge
inoculation of Dryvax. The PBMC samples for subject VRC19
used in this study were obtained 2 months after MVA
immunization (19-MVA) and 4 months after MVA and 1 month
after Dryvax (19-Dryvax). Subject VRC47 received two placebo
injections and one Dryvax immunization. The VRC47 samples
used in this study were drawn 1 and 3 months after Dryvax
vaccination. The sample obtained after 1 month of vaccination
was used to derive the VRC47-38 T cell clone whereas the sample
drawn 3 months post-vaccination was used to generate a vaccinia
line for testing the recognition of the peptides (47-Dryvax,
Figure 9). The HLA class II genotypes for each donor are as
follows: VRC19: DRB1*0701, 150101; DRB4*0103; DRB5*0101;
DQB1*0202, 0602; DPB1*0401, 2701; DQA1*0102, 0201;
DPB1*8501 and VRC47: DRB1*0701; DRB4*0101;
DQB1*0202; DPB1*0301, 0501; DQA1*0201.
Vaccinia specific T cell lines
Isolated PBMC from donors VRC19 and VRC47, samples 19-
Dryvax and 47-Dryvax respectively, were stimulated with WR
vaccinia virus at a multiplicity of infection (MOI) of 0.1. When cells
were actively dividing (day 5–8) they were immortalized using a
murine leukemia virus based retroviral vector carrying the
telomerase gene (hTERT) [59]. This vector preferentially transduces
cells that are dividing, and the procedure results in the selective
transduction of cells that are proliferating in response to antigen
stimulation. Introduction of hTERT allows for long-term culture
and production of large numbers of T cells while maintainingMHC-
restricted antigen-specific reactivity and T cell functions. Lines were
frozen and thawed when needed. After thawing, lines were expanded
by allogeneic stimulation using the mitogen phytohaemagglutinin
(PHA) (Remel, Inc) at 0.5 mg/ml in the presence of irradiated,
allogeneic feeder cells and 100 IU/ml of IL-2.
Generation of vaccinia specific T cell clones
The VRC19 and VRC47 vaccinia stimulated and immortalized
T cell lines described above were cloned by limiting dilution. PHA
allogenic stimulated cells were plated in wells at different cell
concentrations ranging from 10 to 0.1 cells/well. After one or two
stimulations, depending on the growth, a fraction of the cells were
tested for vaccinia reactivity as described below. Cells that
responded to vaccinia infected antigen presenting cells and grew
to large numbers were characterized for CD4, CD8 and then by
TCR Vb expression by flow cytometry or PCR. Cell cultures that
stained with one TCR Vb antibody were considered T cell clones
(TCC). Those that were negative for any of the antibodies were
further tested by PCR to confirm clonality.
Vaccinia virus infection of antigen presenting cells
The antigen presenting cells used in functional assays to
determine the vaccinia reactivity of vaccinia lines and clones were
Epstein-Barr virus (EBV)-transformed autologous lymphoblastoid
cell lines (LCL). LCL were derived from PBMC using EBV isolate
B95.8 [60]. Cryopreserved vaccinia virus (Western Reserve) was
used at a multiplicity of infection (MOI) of 0.1 for the infection of
LCL. To infect the LCL, cells were pre-incubated with virus at a
concentration of 106106 cells/ml for 1 hour. Then the cells were
diluted at 16106 cells/ml and incubated overnight at 37uC,
5%CO2.
Table 2. Recognition of vaccinia proteins for which peptides have been identified using the ‘‘T cell driven’’ approach presented in
this study.
Protein Function, temporal expressiona
Proliferative responses
(11 subjects)b
Antibody recognition
(76 or 126 subjects)c
Other human CD4 epitopes
reported, Method
D13L Rifampicin target/membrane, L 100% 60% Yes, recombinant fragments
A10L precursor p4a of core protein 4a, L 100% 60% Yes, MHC elution and DR1 binding
prediction
A7L 82 kDa large subunit of early gene
transcription factor VETF, L
64% 1%d Yes, recombinant fragments and DR1
binding prediction
F13L EEV membrane protein, L 64% 15% No
A6L Unknown, L 55% 0%d No
H5R Morphogenesis related,
Transcription factor VLTF-4, E
55% 16% No
D1R mRNA capping enzyme, E 27% 7%d Yes, overlapping peptides and DR1
binding prediction
E1L Poly-A polymerase, E 18% 0% No
L1R IMV membrane protein, L 18% 37% Yes, recombinant fragments and
overlapping peptides
A28L Unknown, putative signal peptide, L 0% 0% DR1 binding prediction
aProtein Temporal expression derived from Assarsson et al [ref.58]. L (late) and E (early).
bPercentage of subjects (out of 11) that showed proliferative response to the recombinant antigen [ref.13].
cPercentage of subjects (out of 76 or 126) that showed antibody recognition to the recombinant antigen derived from 5 different studies [refs. 13,54–57].
dProteins tested with 76 subjects.
doi:10.1371/journal.pone.0024091.t002
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Vaccinia reactivity test
T cell lines or clones (256103 cells per well) were cultured alone,
stimulated with PHA (0.5 mg/ml) or in the presence of infected or
uninfected LCL (506103 cells per well) in 96-well U bottom plate
at a final volume of 250 ml of Opti-MEM Reduced Serum
Medium (Invitrogen, Carlsbad, CA). After 48 hours, supernatants
were collected and GM-CSF and TNF-a production was
quantified by ELISA.
Positional scanning decapeptide library and individual
peptides
Both positional scanning libraries and individual peptides were
synthesized using the simultaneous multiple peptide synthesis
technology [61]. The decapeptide library used in this study is a
synthetic N-acetylated, C-terminal amide, L-amino acid combina-
torial peptide library arranged in a positional scanning format [62].
It consists of 200 mixtures in the OX9 format where O represents
one of the 20 natural L-amino acids in a defined position and X
represents all of the natural amino acids, with the exception of
cysteine, in each of the remaining positions [62]. For example, the
first mixture has alanine (A) in position 1 (A1X9) whereas mixture
number 200 has tyrosine (Y) in position 10 (X9Y10). Each OX9
mixture consists of 3.261011 (199) different decapeptides in
approximate equimolar concentration, and the total 610 library
consists of 6.461012 (206199) different peptides. Assuming an
average molecular weight of 1200 for a decapeptide mixture and a
concentration of 100 mg/ml (83 mM), the concentration of each
individual peptide is 2.6610216 M. For the individual peptides,
synthesized for each clone, the purity and identity were character-
ized by liquid chromatography and mass spectrometry.
Library screening and biometrical analysis
Clonal T cells were cultured (256103 cells per well) together
with LCL (506103 cells per well) in microtiter plates in standard T
cell medium containing each of the mixtures of the library at
200 mg/ml. Medium used for cultures consisted RPMI 1640
(Fisher Scientific, Pittsburgh, PA) supplemented with 10% human
serum (Gemini Bio Products, West Sacramento, CA), 1% HEPES
buffer (Fisher Scientific, Pittsburgh, PA), 2-bME at 50 mM, 1%
penicillin-streptomycin (Fisher Scientific, Pittsburgh, PA), 1%
glutamine (Fisher Scientific, Pittsburgh, PA), 1% sodium pyruvate
(Fisher Scientific, Pittsburgh, PA) and 1% non-essential amino
acids (Fisher Scientific, Pittsburgh, PA). Culture supernatants were
harvested at 48 hours and GM-CSF production was determined
by ELISA. The positional scanning based biometrical analysis was
carried out as previously described [20]. Briefly, a positional
scoring matrix was generated by assigning a value of the
stimulatory potential to each of the 20 defined amino acids in
each of the ten positions of the decapeptide library. Based on a
model of independent contribution of individual amino acid to
peptide antigen recognition, the predicted stimulatory score of a
given peptide is the sum of the stimulatory potential of all amino
acids contained in the peptide in each position. Using a web-based
search tool [21] the scoring matrix was applied to rank, according
to their stimulatory score, all the naturally overlapping 10-mer
peptides in the protein sequences within the vaccinia virus
(Western Reserve) protein database. For the biometrical analysis
of clones 19-16 and 19-29 the average of the results of the
positional scanning library data obtained from 3 or 5 different
screenings, respectively, was used to generate their matrix. Using
this matrix a list of predicted peptides for each clone was generated
and the top 35 peptides for clone 19-16 and the top 18 peptides for
clone 19-29 were selected for synthesis. For clones 19-36 and 47-
38, the range of GM-CSF production in response to the mixtures
of the positional scanning library varied significantly between the
different screenings precluding the calculation of an average for
the generation of the matrix. Therefore, a different strategy was
used in which a biometrical analysis for each of the screenings was
carried out. Each screening (2 for clone 19-36 and, 3 for clone 47-
38) was used to build a matrix and to derive a list of predicted
peptides. Fifteen peptides for clone 19-36 were selected which
included the top 5 peptides from each screen and, the top common
peptides within the first 40 top ranked peptides in each of the
screens. For clone 47-38, 21 peptides were selected for synthesis
which included the common peptides between the top 50 peptides
generated in each of the 3 screenings. All synthesized peptides
were tested at 10 and 1 mg/ml with their respective T cell clones
for stimulatory activity based on GM-CSF and TNF-a release.
Cytokine detection. ELISA, Multiplex and ICCS
The assessment of GM-CSF and TNF-a production was
performed using ELISA kits according to the manufacturer (BD
Pharmingen, San Diego, CA). Linear regression standard curves
were used to convert O.D. 492 nm values to specific cytokine
concentrations using Prism. Multiplex cytokine detection was
performed with Milliplex MAP kit (for 6 or 22 cytokines) following
the manufacturer’s directions (Millipore, St. Charles, MO) and
Luminex instrument and Beadlyte software were used for analysis.
For intracellular cytokine staining (ICCS) peptides (10 mg/ml) were
added to 36105 clonal T cells or 56105 T cell lines in 200 ml T cell
media for 6 hours. A total of 0.6–16106 autologous LCL were
added as APC. Brefeldin A was added for 5 hours. Each sample was
stained with anti-CD4 and anti-CD8, fixed, permeabilized and then
stained with anti-IFN-c and anti-TNF-a. Background controls were
T cell clones or lines with LCL and without peptide addition.
Positive controls were T cell clones or lines stimulated with PHA.
HLA restriction
For HLA restriction studies, T cell clones (TCC) together with
uninfected LCL were cultured with peptide in the presence of
10 mg/ml of the following antibodies; anti–HLA-DR (BD
Biosciences), anti–HLA-DQ (BD Biosciences), anti–HLA-DR/
DQ/DP (BD Biosciences) or human IgG2a (BD Biosciences) as an
isotype control. TCC were also tested in the presence of vaccinia
infected LCL in the presence or absence of the same antibodies
listed above. GM-CSF and TNF-a were measured after 48 hours
incubation. Further characterization of the HLA-DR restriction
for donor VRC19 was performed using BLS cells as antigen
presenting cells. Briefly, BLS cells were incubated with peptide for
1 hour at 37C and then washed and cultured with the
corresponding TCC for 48 hours.
Cytolytic activity assay
The cytolytic activity of the vaccinia specific clones was
determined at various effector-to-target (E:T) ratios in a 4 hours
standard CTL assay. Briefly, peptide-pulsed-, vaccinia infected- or
untreated- autologous LCL labeled with 51Cr were used as target
cells. Target cells were incubated with each of the clones in a 96-
well plate. Wells with only labeled target cells were used to
establish the spontaneous 51Cr release whereas wells containing
2.0% igepal CA 630 and target cells were added to determine the
maximum release. After 4 hours incubation, 75 ml of supernatant
was transferred to a flexible plate containing 200 ml of scintillation
fluid. Plates were counted on a Trilux 1450 Microbeta liquid
scintillation counter. Specific percent lysis was calculated as
follows: ((experimental release-spontaneous release)/(maximum
release-spontaneous release)6100).
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Supporting Information
Figure S1 HLA restriction of peptides and vaccinia
recognition determined using single haplotype expres-
sion BLS cells. VRC-19 clones were cultured in the presence of
BLS transfected cells expressing either the DRB5*0101 (DR2a) or
DRB1*1501 (DR2b) haplotypes and their respective specific
peptide at the indicated concentrations. Cultures including
autologous LCL or vaccinia infected LCL were used as controls.
The production of TNF-a and GM-CSF detected in the
supernatants of duplicate wells after 48 hours of stimulation is
shown.
(PDF)
Table S1 Matrices derived from screening of decapep-
tide positional scanning library with clones VRC19-16,
VRC19-29, VRC19-36, and VRC47-38.
(PDF)
Table S2 Peptides identified from positional scanning
based biometrical analysis for each T cell clone.
(PDF)
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